Eli Lilly And Co LLY might see a significant boost due to supply issues at competitor Novo Nordisk A/S NVO, according to Reddit user serkankster.
It was noted that Eli Lilly’s weight loss drug Zepbound resolved previous supply issues, especially in major cities. The Redditor highlighted recent fires at Novo Nordisk’s facilities could further limit their supply, potentially benefiting Eli Lilly.
Redditor serkankster commented, “The revenues of $LLY has mostly been driven by the GLP-1 weight loss drug which was experiencing a lot of supply issues.” The user also speculated on a potential stock split for Eli Lilly, driven by its strong performance and high share price nearing $1,000.
Another user, LetsPlay30k, echoed this sentiment, suggesting a stock split is “very likely.”
Also Read: Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
While some Redditors, like Electrical-Judge3789 and 3ebfan, clarified the fires at Novo Nordisk were not in their manufacturing areas, serkankster mentioned the fires affected a factory site under construction and two office buildings.
They also noted Novo Nordisk’s recent acquisition of Catalent, a major contract manufacturer for Eli Lilly, could impact its supply chain.
Eli Lilly’s potential was further supported by cryptovorrection69, who highlighted an upcoming FDA approval for an Alzheimer’s drug. It “could give them a sizable jump when announced,” he commented.
Another user, twostroke1, mentioned Eli Lilly's ongoing $10 billion plant construction in Indiana, set to increase their weight loss drug supply by 2026. The user is bullish on this development: “That's when the real supply will skyrocket. Whether investors are pricing this in already or not is anyone's guess. But looking at the performance of Lilly over the past decade, I'd be very hesitant to bet against it,” he said.
Reddit users are closely watching these developments, with many expressing optimism about Eli Lilly’s stock performance and supply capabilities.
Read Next: Novo Nordisk’s Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
Photos: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.